- Home
- OPCH vs BIO Comparison
OPCH vs BIO Comparison
Compare OPCH & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- BIO
- Stock Information
- Founded
- OPCH N/A
- BIO 1952
- Country
- OPCH United States
- BIO United States
- Employees
- OPCH N/A
- BIO N/A
- Industry
- OPCH Medical/Nursing Services
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- OPCH Health Care
- BIO Industrials
- Exchange
- OPCH Nasdaq
- BIO Nasdaq
- Market Cap
- OPCH 5.3B
- BIO 6.0B
- IPO Year
- OPCH N/A
- BIO N/A
- Fundamental
- Price
- OPCH $30.03
- BIO $257.04
- Analyst Decision
- OPCH Strong Buy
- BIO Strong Buy
- Analyst Count
- OPCH 7
- BIO 4
- Target Price
- OPCH $35.86
- BIO $324.25
- AVG Volume (30 Days)
- OPCH 1.5M
- BIO 374.5K
- Earning Date
- OPCH 07-30-2025
- BIO 07-31-2025
- Dividend Yield
- OPCH N/A
- BIO N/A
- EPS Growth
- OPCH N/A
- BIO N/A
- EPS
- OPCH 1.25
- BIO N/A
- Revenue
- OPCH $5,185,122,000.00
- BIO $2,541,100,000.00
- Revenue This Year
- OPCH $13.22
- BIO N/A
- Revenue Next Year
- OPCH $8.52
- BIO $3.49
- P/E Ratio
- OPCH $23.91
- BIO N/A
- Revenue Growth
- OPCH 16.98
- BIO N/A
- 52 Week Low
- OPCH $21.39
- BIO $211.43
- 52 Week High
- OPCH $35.53
- BIO $387.99
- Technical
- Relative Strength Index (RSI)
- OPCH 34.78
- BIO 65.41
- Support Level
- OPCH $30.79
- BIO $245.87
- Resistance Level
- OPCH $31.22
- BIO $264.68
- Average True Range (ATR)
- OPCH 0.66
- BIO 7.34
- MACD
- OPCH -0.16
- BIO 1.84
- Stochastic Oscillator
- OPCH 4.94
- BIO 78.94
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.